A Current Review of Systemic Lupus Erythematosus Treatment Using Monoclonal Antibodies

Abstract

Lupus erythematosus (SLE) is an autoimmune disease that affects the body's immune system, heterogeneous, and inflammatory autoimmune diseases. These diseases, affect multiple tissues and organs. The most frequent kind of lupus is systemic lupus erythematosus (SLE). SLE is an autoimmune illness in which the immune system targets the body's own tissues, resulting in extensive inflammation and tissue destruction in the organs involved. Joints, skin, brain, lungs, kidneys, and blood vessels can all be affected. It examines to be B-cell disease in which autoantibodies attack the cells themselves. Systemic lupus erythematosus autoimmune diseases involve different treatment methods. These abnormalities are due to the presence of autoantibodies, and these autoantibodies contribute to the degeneration of our immune system. In this review, we will focus on various therapies including SLE treatments, such as B-cell therapy, cytokine therapy, interferon targets, and anticomplementary therapies, all of which have become challenging. We will also discuss post-marketing use and ongoing clinical trials, as well as safety and effective doses.